Last updated on August 2017

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain


Brief description of study

This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.

Clinical Study Identifier: NCT03181984

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Ke Wang

Peking University First Hospital
Beijing, China
  Connect »